Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
When will the presidential race be called? Here's what to know.
Recommended
Map shows parts of western NC open for tourism
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Structure Therapeutics Inc.
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
October 31, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
September 17, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
August 27, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
August 26, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
August 08, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
June 07, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
June 05, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
June 03, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
June 03, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
May 09, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
March 08, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
March 08, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
December 18, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
September 29, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
August 03, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
June 07, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics to Present at Jefferies Healthcare Conference
May 31, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
May 25, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
May 18, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 30, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Tickers
GPCR
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02, 2023
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors
January 18, 2023
From
Structure Therapeutics Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.